CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

@article{Su2016CRISPRCas9ME,
  title={CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients},
  author={S. Su and B. Hu and J. Shao and Bin Shen and Juan Du and Yinan Du and Jiankui Zhou and Lixia Yu and Lianru Zhang and Fangjun Chen and H. Sha and Lei Cheng and F. Meng and Z. Zou and X. Huang and Baorui Liu},
  journal={Scientific Reports},
  year={2016},
  volume={6}
}
Strategies that enhance the function of T cells are critical for immunotherapy. One negative regulator of T-cell activity is ligand PD-L1, which is expressed on dentritic cells (DCs) or some tumor cells, and functions through binding of programmed death-1 (PD-1) receptor on activated T cells. Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of PD-1. We showed that the gene knockout of PD-1 by electroporation of plasmids encoding… Expand
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
PD-1 and its ligands in tolerance and immunity.
...
1
2
3
4
...